Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Upgraded by Wall Street Zen

Key Points

• Lexicon Pharmaceuticals has been upgraded by Wall Street Zen from a "hold" to a "buy" rating, reflecting positive analyst sentiment.
• Citigroup raised its price target for Lexicon Pharmaceuticals from $1.20 to $1.90, while HC Wainwright set a target at $4.00, indicating an overall confidence from analysts.
• The company reported a positive quarterly earnings surprise, with earnings of $0.01 per share, significantly surpassing analysts' expectations of a loss.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday.

A number of other analysts have also recently weighed in on the company. Citigroup boosted their price target on Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the stock a "buy" rating in a research report on Thursday, August 7th. HC Wainwright reaffirmed a "buy" rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research report on Tuesday, September 2nd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Lexicon Pharmaceuticals in a research report on Saturday, September 27th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $3.23.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ:LXRX opened at $1.41 on Friday. Lexicon Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $2.18. The business has a 50-day moving average of $1.16 and a two-hundred day moving average of $0.87. The stock has a market capitalization of $512.39 million, a P/E ratio of -4.27 and a beta of 1.23. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.16 and a quick ratio of 4.16.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.09. Lexicon Pharmaceuticals had a negative return on equity of 83.63% and a negative net margin of 206.43%.The company had revenue of $28.87 million during the quarter, compared to analysts' expectations of $4.87 million. On average, equities research analysts predict that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Large investors have recently bought and sold shares of the business. Hudson Bay Capital Management LP bought a new stake in Lexicon Pharmaceuticals during the 2nd quarter worth approximately $26,000. R Squared Ltd bought a new stake in Lexicon Pharmaceuticals during the 2nd quarter worth approximately $28,000. Catalyst Funds Management Pty Ltd bought a new position in Lexicon Pharmaceuticals in the 2nd quarter valued at $51,000. Straight Path Wealth Management bought a new position in Lexicon Pharmaceuticals in the 1st quarter valued at $29,000. Finally, Vanguard Personalized Indexing Management LLC boosted its position in Lexicon Pharmaceuticals by 77.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 65,330 shares of the biopharmaceutical company's stock valued at $62,000 after buying an additional 28,594 shares during the last quarter. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.